ClinicalTrials.gg
CompletedNCT06099652Updated Nov 20, 2025

Evaluation of 611 in Chinese Adults With Moderate to Severe Chronic Obstructive Pulmonary Disease

A Phase 2 interventional study of 611 300 mg Q2W and 611 450 mg Q2W in Pulmonary Disease, Chronic Obstructive, sponsored by Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.. Completed at 3 sites in China. Open to participants aged 40 Years to 85 Years. Per ClinicalTrials.gov, last updated 2025-11-20.

Sponsored by Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. (part of 3SBio Inc.) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
142
Allocation
Randomized
Ages
40 Years to 85 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 404 studies in Pulmonary Disease, Chronic Obstructive with a site in China — 108 open to participants now, 125 under way, 15 of them phase 3. Pulmonary Disease, Chronic Obstructive · China.

Enrollment
147th of 286
142 · median 155
Started
2023
with 44 others
Phase 2
33 of 404
13 open now
Registered
275th of 404
by date

Among the 404 studies in Pulmonary Disease, Chronic Obstructive with a site in China, this one is the 147th largest by enrollment of the 286 interventional ones that give a count, is one of 45 that started in 2023, is one of 33 in phase 2, and was the 275th registered.

Pulmonary Disease, Chronic Obstructive

5,523 studies on the registry are indexed under Pulmonary Disease, Chronic Obstructive; 857 are open to participants now.

Browse Pulmonary Disease, Chronic Obstructive studies →

Open to participants now

108 of the 404 studies in Pulmonary Disease, Chronic Obstructive with a site in China are open now. Recruiting first, the newest first:

103 more — sign in →

All 108 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 557 Pulmonary Disease, Chronic Obstructive studies recruiting now, 306 (55%) set no upper age limit and 82 (15%) stop at 75 or younger; 29 take children under 18; 89 take healthy volunteers.

This study: 40 Years to 85 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 404 studies in Pulmonary Disease, Chronic Obstructive with a site in China, or all of them as a file.
02

Study summary

The primary objective of the study was to evaluate the efficacy and safety of 611 in Chinese adults with moderate to severe COPD.

Read the detailed description

The maximum study duration was 28 weeks per participants, including a screening period of up to 4 weeks, a 16-week randomized treatment period, and a 8-week follow-up period.

03

Conditions studied

  • Pulmonary Disease, Chronic Obstructive
04

Who can participate

Ages eligible
40 Years to 85 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Subject must be able to understand and comply with the requirements of the study. and must participate voluntarily and sign the written .
  2. Male or female adults ages 40 to 85 years old when signing the informed consent.
  3. ≥16 kg/m2.
  4. Documented diagnosis of for at least one year prior to enrolment.
  5. Post-bronchodilator /FVC \< 0.70 and post-bronchodilator FEV1 % predicted >30% and ≤70%.
  6. Current or former smokers with a smoking history of ≥10 pack-years or environmental exposure to biofuel fumes ≥10 years
  7. Documented history of ≥ 2 moderate or ≥ 1 severe COPD exacerbations within 12 months prior to enrolment.
  8. Background triple therapy (ICS + LABA + LAMA) for 3 months prior to randomization with a stable dose of medication for ≥1 month prior to randomization; Double therapy (LABA + LAMA) allowed if ICS is .
  9. Patients with blood eosinophils ≥200 cells/microliter at screening.
  10. Female subjects of reproductive age (and their male partners) and male subjects (and their female partners) must use highly effective throughout the study period and for at least 3 months after the last dose. The subjects had no plans to pregnancy, donate sperm or donate egg during the whole study period and for at least 3 months after the last dose.

Exclusion criteria

Exclusion Criteria:

  1. Significant pulmonary disease other than (e.g., active tuberculosis,lung cancer, bronchiectasis, sarcoidosis, lung fibrosis, pulmonary hypertension, interstitial lung disease, etc)
  2. Diagnosed pulmonary or systemic disease associated with elevated peripheral eosinophil counts.
  3. A current diagnosis of asthma or history of asthma according to the Global Initiative for Asthma (GINA) guidelines or other accepted guidelines.
  4. Diagnosis of α-1 anti-trypsin deficiency.
  5. Cor pulmonale, evidence of right cardiac failure
  6. Any history of vernal keratoconjunctivitis (VKC) and atopic keratoconjunctivitis (AKC).
  7. A participant with a history of renal, hepatic, cardiovascular, metabolic, neurologic, hematologic, ophthalmologic, respiratory, gastrointestinal, cerebrovascular or other significant medical illness or disorder which, in the judgment of the Investigator, could interfere with the study or require treatment that might interfere with the study.
  8. Patients who have active , or infections as determined by positive results at Screening.
  9. Hypercapnia requiring Bi-level ventilation.
  10. AECOPD as defined in inclusion criteria within 4 weeks prior to screening or randomization.
  11. History of, or planned pneumonectomy or lung volume reduction surgery.
  12. Treatment with oxygen of more than 12 hours per day.
  13. Known with allergic or intolerant to mometasone furoate spray or 611/placebo.
  14. Any reason which, in the opinion of investigator, would prevent the subject from participating in the study.
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
142 participants (actual)

Study arms

  • Experimental
    group A

    611 300 mg Q2W, subcutaneous (SC) injection

    Drug: 611 300 mg Q2W

  • Experimental
    group B

    611 450 mg Q2W, subcutaneous (SC) injection

    Drug: 611 450 mg Q2W

  • Placebo comparator
    placebo group

    placebo Q2W, subcutaneous (SC) injection

    Drug: Matching placebo

Interventions

  • 611 subcutaneous (SC) injection

  • 611 subcutaneous (SC) injection

  • DrugMatching placebo

    placebo subcutaneous (SC) injection

06

What researchers measure

Primary outcomes

  1. Change from baseline in pre-bronchodilator FEV1 at Week 16

    FEV1 is the Forced expiratory volume in one second at study site

    Time frame: up to Week 16

Secondary outcomes

  1. Change from baseline in Chronic Obstructive Pulmonary Disease assessment tool (CAT) score

    Chronic Obstructive Pulmonary Disease assessment tool (CAT) score ranges from 0 to 40, a higher score indicating a higher impact on health status.

    Time frame: up to Week 16

  2. Change from baseline in St. George's Respiratory Questionnaire (SGRQ) total score

    St. George's Respiratory Questionnaire (SGRQ) is a questionnaire designed to measure and quantify health-related health status in adult patients with chronic airflow limitation. A global score ranges from 0 to 100. Lower score indicates better quality of life.

    Time frame: up to Week 16

  3. Percentage of participants with a decrease in SGRQ total score of ≥ 4 points from baseline to Week 16

    St. George's Respiratory Questionnaire (SGRQ) is a questionnaire designed to measure and quantify health-related health status in adult patients with chronic airflow limitation. A global score ranges from 0 to 100. Lower score indicates better quality of life.

    Time frame: up to Week 16

  4. Annualized rate of moderate to severe COPD exacerbations in participants

    Moderate or severe COPD exacerbation is defined by symptomatic worsening of COPD. Moderate:Use of systemic corticosteroids; and/or use of antibiotics; Severe:An inpatient hospitalization due to COPD

    Time frame: up to Week 16

  5. Time to first Moderate or severe COPD exacerbation

    Moderate or severe COPD exacerbation is defined by symptomatic worsening of COPD. Moderate:Use of systemic corticosteroids; and/or use of antibiotics; Severe:An inpatient hospitalization due to COPD

    Time frame: up to Week 16

  6. Adverse events (AEs), measurement of vital signs,physical examination,electrocardiogram and laboratory tests at each visit.

    The incidence and severity of treatment emergent adverse event (TEAE), including Serious Adverse Event (SAE), as well as clinical symptoms, and any abnormalities of vital signs, physical examinations,electrocardiogram,laboratory tests and, etc.

    Time frame: Up to 24 Weeks

  7. 611 Concentration in Serum

    The concentration of 611 in Serum

    Time frame: Up to 24 Weeks

  8. Percentage of Participants with Anti-drug Antibodies and Neutralizing Antibodies

    Immunogenicity assessment will be based on Anti-drug Antibodies (ADAs) response and development of Neutralizing Antibodies (NABs). Percentage is calculated based on the number of evaluable participants and was calculated by number of participants with treatment-emergent positive anti-drug antibodies / number of evaluable participants \* 100%.

    Time frame: Up to 24 Weeks

  9. Change in serum concentrations of PD variables

    PD variables included Pulmonary and activation-regulated chemokine (PARC),IgE,blood eosinophil counts and fibrinogen

    Time frame: Up to 24 Weeks

07

Study locations

3 sites
  • China-Japan Friendship Hospital
    Beijing, Beijing Municipality 100029, China
  • Shenzhen People's Hospital
    Shenzhen, Guangdong 518020, China
  • Zhongshan Hospital affiliated to Fudan University
    Shanghai, Shanghai Municipality 200032, China
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Dec 2023 to primary completion in Apr 2025, 16 months.

Of 118 industry-sponsored phase 2 interventional studies under Pulmonary Disease, Chronic Obstructive, half reached primary completion within 14 months of starting (the median), counting those still running; a quarter within 7 and three quarters within 20. This study's 16 months is above that.

Counting every sponsor, half of 165 studies reached it within 17 months; a quarter within 10 and three quarters within 31.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 19, 2023
First posted
Oct 25, 2023
StartActual
Dec 8, 2023
Primary completionActual
Apr 15, 2025
CompletionActual
Jun 18, 2025
Last update
Nov 20, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 20, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06099652
Responsible party
Sponsor
First posted
Oct 25, 2023
Start date
Dec 8, 2023
Primary completion
Apr 15, 2025
Completion
Jun 18, 2025
Last update
Nov 20, 2025

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Camtarkibart

Start the discussion